RTI Surgical up 18% premarket

Shares of RTI Surgical (RTIX) are poised for a gap up at the open. Investors appear to like the prospects of two new products launched today.

NanOss Bioactive 3D, a synthetic three dimensional bioscaffold that supports bone formation and map3 Cellular Allogeneic Bone Graft, an implant that generates and maintains new bone are now available for commercial sale.

Consensus EPS and revenue estimates for 2014 and 2015 are $0.07/share on revenues of $237M and $0.13/share on revenues of $268M, respectively.

162 mutual funds have positions, down from 197 a year earlier.

Comments (1)
  • michael brod
    , contributor
    Comments (3) | Send Message
    This is an oft told tale by Management. Lofty predictions leading to the disappointment of unmet expectations. That 162 mutual funds own the stock just reinforces the concept of herd mentality. The relevant question is how many of those funds are actually in the black with their RTIX investment. Certainly the latest "institutional" investor, who bought in at $4.49, or thereabouts isn't smiling.


    This Company is running on gas alright, but not the kind that comes from a pump.
    14 Mar 2014, 01:00 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs